About HighTide Therapeutics
HighTide Therapeutics is a company based in Rockville (United States) founded in 2011. HighTide Therapeutics has raised $107 million across 2 funding rounds from investors including CITIC, TCM Health Care and Yuexiu Capital. The company has 70 employees as of December 31, 2024. HighTide Therapeutics operates in a competitive market with competitors including NGM Biopharmaceuticals, Ironwood Pharma, Nimbus Therapeutics, Adocia and Altimmune, among others.
- Headquarter Rockville, United States
- Employees 70 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Hightide Therapeutics Inc
-
Annual Revenue
Not available
-
Net Profit
-$53.3 M (USD)60.12as on Dec 31, 2024
-
EBITDA
-$61.27 M (USD)-4.72as on Dec 31, 2024
-
Total Equity Funding
$107 M (USD)
in 2 rounds
-
Latest Funding Round
$107 M (USD), Series C
Jan 05, 2023
-
Investors
CITIC
& 5 more
-
Employee Count
70
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of HighTide Therapeutics
HighTide Therapeutics is a publicly listed company on the HKEX with ticker symbol 2511 in Hong Kong, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
People of HighTide Therapeutics
Unlock access to complete
Unlock access to complete
Funding Insights of HighTide Therapeutics
HighTide Therapeutics has successfully raised a total of $107M across 2 strategic funding rounds. The most recent funding activity was a Series C round of $107 million completed in January 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in HighTide Therapeutics
HighTide Therapeutics has secured backing from 6 investors, including institutional and venture fund investors. Prominent investors backing the company include CITIC, TCM Health Care and Yuexiu Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Yuexiu Capital is engaged in financial services and asset management.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
TCM Health Care is focused on Traditional Chinese Medicine therapies.
|
Locked | Locked | Locked |
Investor details for HighTide Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by HighTide Therapeutics
Investment portfolio details for HighTide Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - HighTide Therapeutics
Detailed financials for HighTide Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Hightide Therapeutics Comparisons
Peer comparison for HighTide Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of HighTide Therapeutics
HighTide Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as NGM Biopharmaceuticals, Ironwood Pharma, Nimbus Therapeutics, Adocia and Altimmune, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Biologics are developed for cardio-metabolic and liver diseases.
|
|
| Locked | Locked | Locked |
Therapeutics for gastrointestinal disorders, including linaclotide, are developed.
|
|
| Locked | Locked | Locked |
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for diabetes and obesity treatment are developed.
|
|
| Locked | Locked | Locked |
Vaccines for infectious diseases and solid tumors are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for gastrointestinal, cardio-renal, and metabolic diseases are developed.
|
Detailed competitors of HighTide Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Hightide Therapeutics
Complete news archive for HighTide Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about HighTide Therapeutics
HighTide Therapeutics was founded in 2011 and raised its 1st funding round 9 years after it was founded.
HighTide Therapeutics is headquartered in Rockville, United States. It is registered at Rockville, Maryland, United States.
HighTide Therapeutics is a funded company, having raised a total of $107M across 2 funding rounds to date.
As of Dec 31, 2024, the latest employee count at HighTide Therapeutics is 70.
Developer of small molecule based therapeutics for the treatment of liver, gastrointestinal, and metabolic disorders. The companys lead product candidate HTD-1801 used for the treatment of primary sclerosing cholangitis, NAFLDNASH, and hypercholesterolemia. Other products of the company include HTD4010 used for the treatment of acute pancreatitis, HTD1804 for obesiry, HTD1805 for metabolic disease, and HTD2802 for IBD.
HighTide Therapeutics's top competitors include Ironwood Pharma, Nimbus Therapeutics and Adocia.
Yes, HighTide Therapeutics is publicly traded on HKEX under the ticker symbol 2511.
HighTide Therapeutics has 6 investors. Key investors include CITIC, TCM Health Care, Yuexiu Capital, Hongde Fund Management, and Cowin Capital.
The ticker symbol of HighTide Therapeutics is 2511 on HKEX.